

Original Article

Evaluating the Role of Post-Thrombectomy MRI in Predicting Functional Recovery in Basilar Artery Occlusion

Nahal Farhani¹, Marco Ayroso², Susan Alcock² and Jai Shankar² 

¹Department of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada and ²Department of Radiology, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada

ABSTRACT: Background: Stroke due to basilar artery occlusion (BAO) carries poor outcomes despite advancements in endovascular therapy (EVT). Predictors of recovery remain underexplored. This study evaluates clinical and imaging predictors of outcomes following EVT, including a Critical Area Diffusion Score (CADS), assessing infarct location and extent in critical brainstem regions on post-EVT MRI. **Methods:** This retrospective study analyzed 48 BAO patients treated with EVT at a provincial stroke center (2015–2021). Patients were categorized by outcomes (favorable: modified Rankin Scale [mRS] 0–3; unfavorable: mRS 4–6). Clinical, demographic and imaging data – age, baseline National Institutes of Health Stroke Scale (NIHSS), reperfusion success (thrombolysis in cerebral infarction [TICI] 2b–3) and post-EVT CADS from diffusion-weighted MRI – were assessed using univariate and multivariate logistic regression. **Results:** Patients with favorable outcomes were younger (median 64.0 vs. 73.0 years, $p = 0.031$), had lower NIHSS scores at presentation (median 8 vs. 16, $p = 0.018$) and achieved higher successful reperfusion rates (81.0% vs. 48.1%, $p = 0.020$). CADS ≤ 3 was linked to better outcomes (median mRS 3 vs. 5, $p = 0.026$) and higher odds of recovery in univariate analysis (OR = 10.89, $p = 0.038$). However, in multivariate analysis, CADS was not an independent predictor, with successful reperfusion (OR = 18.8, $p = 0.044$) as the strongest factor. **Conclusion:** Age, NIHSS scores and successful reperfusion predict recovery in BAO patients undergoing EVT. Although CADS ≤ 3 is linked to favorable outcomes, it is not independently predictive. CADS holds promise as a prognostic tool, but its utility should be considered alongside clinical markers to enhance outcome prediction in BAO.

RÉSUMÉ: Évaluation du rôle de l'IRM post-thérapie endovasculaire dans la prédiction de la récupération fonctionnelle en cas d'occlusion de l'artère basilaire. **Contexte :** Malgré les progrès de la thérapie endovasculaire (TEV), les AVC attribuables à une occlusion de l'artère basilaire (OAB) entraînent une évolution défavorable de l'état des patients. De leur côté, les facteurs prédictifs de la récupération restent sous-explorés. Cette étude entend donc évaluer les prédicteurs cliniques et d'imagerie de l'évolution de l'état des patients après une TEV, y compris le *Critical Area Diffusion Score* (CADS), évaluant, au moyen d'une IRM post-TEV, la localisation et l'étendue de l'infarctus dans les régions critiques du tronc cérébral. **Méthodes :** Cette étude rétrospective a analysé 48 patients victimes d'une OAB et ayant bénéficié d'une TEV dans un centre provincial des AVC (2015-2021). Ces patients ont été classés en fonction de l'évolution de leur état (favorable : échelle modifiée de Rankin [emR] 0-3 ; défavorable : emR 4-6). Les données cliniques, démographiques et d'imagerie (âge, score initial à la *National Institutes of Health Stroke Scale* [NIHSS], succès de la reperfusion [thrombolyse dans l'infarctus cérébral : 2b-3] et CADS post-TEV à partir d'un examen d'IRM de diffusion) ont été évaluées à l'aide d'un modèle de régression logistique univariée et multivariée. **Résultats :** Les patients dont l'évolution de l'état était favorable étaient plus jeunes (médiane : 64,0 contre 73,0 ans ; $p = 0,031$), avaient des scores initiaux à la NIHSS plus bas (médiane : 8 contre 16 ; $p = 0,018$) et avaient obtenu des taux de reperfusion réussie plus élevés (81,0 % contre 48,1 % ; $p = 0,020$). Un CADS égal ou supérieur à 3 était par ailleurs lié à une évolution de l'état des patients davantage favorable (score médian à l'emR : 3 contre 5 ; $p = 0,026$) et à des chances plus élevées de récupération dans le cadre d'une analyse univariée (RC = 10,89 ; $p = 0,038$). Dans le cadre d'une analyse multivariée, le CADS n'était cependant pas un facteur prédictif indépendant, une reperfusion réussie (RC = 18,8 ; $p = 0,044$) étant le facteur le plus important. **Conclusion :** L'âge, les scores à la NIHSS et une reperfusion réussie prédisent la récupération chez les patients victimes d'une OAB qui subissent une TEV. Bien qu'un CADS égal ou supérieur à 3 soit lié à une évolution favorable de l'état des patients, il n'est pas prédictif de manière indépendante. Le CADS demeure un outil pronostique prometteur, mais son utilité doit être envisagée de concert avec des marqueurs cliniques pour améliorer la prédiction de l'évolution de l'état des patients victimes d'une OAB.

Keywords: Basilar artery occlusion; magnetic resonance imaging; Critical Area Diffusion Score (CADS); endovascular thrombectomy; acute ischemic stroke

(Received 2 January 2025; final revisions submitted 21 May 2025; date of acceptance 9 June 2025)

Corresponding author: Jai Shankar; Email: shivajail@gmail.com

Cite this article: Farhani N, Ayroso M, Alcock S, and Shankar J. Evaluating the Role of Post-Thrombectomy MRI in Predicting Functional Recovery in Basilar Artery Occlusion. *The Canadian Journal of Neurological Sciences*, <https://doi.org/10.1017/cjn.2025.10347>

© The Author(s), 2025. Published by Cambridge University Press on behalf of Canadian Neurological Sciences Federation. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.

Highlights

- Lower CADS (≤ 3) post-EVT were linked to better 90-day outcomes, highlighting the role of imaging markers in BAO outcome prediction.
- Younger age, lower NIHSS and successful reperfusion (mTICI 2b–3) were key factors for improved recovery.
- BAO stroke outcomes are multifactorial, shaped by clinical, procedural and imaging factors.

Introduction

Intracranial large vessel occlusion is the most disabling cause of stroke accounting for 24–46% of acute ischemic strokes.¹ Among these, approximately 10% are caused by basilar artery occlusion (BAO), a condition with particularly poor outcomes.² Even with recent advances in the best medical treatment and endovascular therapy (EVT), 68–80% of patients with BAO die or are left severely disabled.^{3,4}

The benefits of EVT for BAO remained unclear due to mixed evidence from earlier trials like BASICS and BEST, which failed to show a significant benefit. Nevertheless, these trials indicated potential EVT benefits for BAO patients with moderate-to-severe symptoms.^{3–6} Recently, newer trials such as ATTENTION and BAOCHÉ demonstrated a clear benefit of EVT in reducing disability and mortality in BAO patients, further solidifying EVT's role, particularly in those with moderate-to-severe symptoms.^{7–10} However, even in these studies, the mortality and disability rates following EVT remain high. In the ATTENTION trial, approximately 55% of patients in the EVT group had a significant disability (modified Rankin Scale, mRS > 3), and 35% died within 90 days. Similarly, in the BAOCHÉ trial, around 50% of EVT-treated patients experienced severe disability, with a 31% mortality rate.^{5,8} This underscores the need for a deeper understanding of the factors that influence recovery trajectories and the critical importance of timely and effective reperfusion therapies.

Several studies have attempted to predict outcomes in BAO strokes.^{11–14} For instance, complete reperfusion (modified thrombolysis in cerebral infarction [mTICI] score 2b–3) has been identified as the strongest predictor of favorable recovery, surpassing factors like baseline National Institutes of Health Stroke Scale (NIHSS) scores and posterior circulation collateral flow.¹⁵ Additionally, patient characteristics such as age, NIHSS score, diabetes and hypertension have been linked to outcomes.¹⁶ Cereda et al.¹⁷ introduced the Critical Area Perfusion Score (CAPS), an imaging marker that assesses the extent of brainstem hypoperfusion. They demonstrated that limited hypoperfusion (CAPS ≤ 3) before EVT strongly predicts favorable outcomes in patients with complete reperfusion. Recently, Karamchandani et al.¹⁸ further validated the utility of pre-procedural perfusion imaging, including CAPS, for predicting final infarct volume after EVT in patients with BAO, reinforcing its prognostic value.

In parallel to their work, we utilized the Critical Area Diffusion Score (CADS) in diffusion-weighted MRI (DWI-MRI) post-EVT to evaluate its predictive accuracy for outcomes. Unlike the original CAPS, which assesses brainstem hypoperfusion, CADS does not measure perfusion but rather quantifies the extent and location of infarction within critical brainstem regions. The aim of our study is to identify predictors of favorable recovery including CADS.

Methods

Design and sample

This retrospective observational study aimed to collect data on BAO stroke patients who received EVT at our provincial





CADS Points	Region	Stroke Examples
1	1 cerebellar hemisphere	
2	2 cerebellar hemispheres	
2	Pons	
2	Midbrain and/or Thalamus	

Figure 1. Critical Area Diffusion Score (CADS). Illustrative examples of stroke infarcts (highlighted in blue) on diffusion-weighted imaging (DWI) for scoring CADS: involvement of a single cerebellar hemisphere (1 point), bilateral cerebellar hemispheres (2 points), pons (2 points) and midbrain or thalamus (2 points). Higher scores represent greater involvement of critical brainstem structures.

comprehensive stroke center. Ethics approval was obtained from the University of Manitoba Health Research Ethics Board (REB number: HS22427 (H2018:506)).

The study included consecutive patients with acute ischemic stroke due to BAO who underwent EVT between January 1, 2015, and December 31, 2021. Patients were identified on admission and urgently assessed by the stroke team, including evaluations for thrombolysis and thrombectomy eligibility.

Inclusion criteria were (1) age ≥ 18 years; (2) pre-stroke modified Rankin Scale (mRS) 0–3; (3) no intracranial hemorrhage; (4) no well-established stroke on imaging; and (5) symptom onset within 24 hours.

Endovascular thrombectomy (EVT)

EVT was performed under conscious sedation or general anesthesia. Fellowship-trained interventional neuroradiologists and neurosurgeons conducted the EVT, with patients closely monitored in the high-observation unit for at least 24 hours post-procedure. Aspiration or stent retriever or a combination of the two were used, depending on the operators' preference and the occlusion characteristics.

Data collection and imaging assessment

Clinical, demographic and imaging data were collected including age, gender, blood pressure, blood glucose, low-density lipoprotein, NIHSS, wake-up stroke status, thrombolysis administration and mTICI scores. Baseline, discharge and 90-day post-stroke mRS scores were retrieved from charts or by interviewing patients and families. Reperfusion was assessed using the TICI scale. Chart reviews were conducted in medical records department. Infarct size and location were quantified using the CADS, adapted from the original CAPS criteria¹⁷ and applied specifically to post-EVT diffusion-weighted MRI (DWI). The CADS assigns points based on the involvement of critical posterior circulation structures: one cerebellar hemisphere (1 point), bilateral cerebellar hemispheres (2 points), pons (2 points) and midbrain or thalamus (2 points) (Figure 1). A higher CADS indicates a more extensive infarction involving critical brainstem structures, potentially correlating with poorer clinical outcomes. Imaging analyses

Table 1. Patient demographic, clinical characteristics and stroke presentation details by mRS

	Total N = 48	90-day mRS ≤ 3 n = 21	90-day mRS > 3 n = 27	P-value
Age, yr, median (IQR)	69.5 (57.8–82.0)	64.0 (48.0–73.0)	73.0 (66.0–83.0)	0.031*
Male, n (%)	31 (64.6)	11 (52.4)	20 (74.1)	0.119
Hyperlipidemia, n (%)	(46) 23 (50.0)	10 (47.6)	(25) 13 (52.0)	0.767
Hypertension, n (%)	(46) 25 (54.3)	11 (52.4)	(25) 14 (56.0)	0.806
Smoking, n (%)	(26) 6 (23.1)	(14) 2 (14.3)	(12) 4 (33.3)	0.251
CAD, n (%)	(46) 11 (23.9)	5 (23.8)	(25) 6 (24.0)	0.988
Diabetes, n (%)	(47) 14 (29.8)	5 (23.8)	(26) 9 (34.6)	0.421
AFib, n (%)	(46) 9 (19.6)	5 (23.8)	(25) 4 (16.0)	0.506
Prior stroke, n (%)	(46) 7 (15.2)	1 (4.8)	(25) 6 (24.0)	0.070
Prior ICH, n (%)	(46) 2 (4.3)	1 (4.8)	(25) 1 (4.0)	0.900
Wake-up stroke, n (%)	(47) 10 (21.3)	6 (28.6)	(26) 4 (15.4)	0.272
NIHSS at presentation, median (IQR)	(47) 13 (7–19)	8 (4–16)	(26) 16 (10–21)	0.018*
SBP, mmHg, mean (SD)	(42) 160.7 (31.1)	(18) 152.3 (23.4)	(24) 167.1 (35.0)	0.129
DBP, mmHg, mean (SD)	(42) 86.2 (12.1)	(18) 85.0 (13.1)	(24) 87.0 (11.6)	0.596
Blood glucose, mmol/L (SD)	(46) 8.6 (3.1)	(19) 7.7 (2.2)	9.2 (3.5)	0.107
Hemoglobin A1c, mmol/mol (SD)	(30) 6.2 (1.4)	(12) 6.3 (1.4)	(18) 6.1 (1.4)	0.736
LDL, mmol/L, SD	(27) 2.3 (1.0)	(15) 2.4 (1.1)	(12) 2.3 (1.0)	0.912
Intravenous thrombolysis, n (%)	18 (37.5)	9 (42.9)	9 (33.3)	0.499
TICI 2b–3, n (%)	27 (56.3)	17 (81.0)	13 (48.1)	0.020*
Tip of BAO, n (%)	(46) 31 (67.4)	(20) 14 (70.0)	(26) 17 (65.4)	0.741
Middle of BAO, n (%)	(46) 23 (50.0)	(20) 8 (40.0)	(26) 15 (57.7)	0.234
Distal of BAO, n (%)	(46) 19 (41.3)	(20) 6 (30.0)	(26) 13 (50.0)	0.172
V4-BAO, n (%)	(45) 16 (35.6)	(20) 5 (25.0)	(25) 11 (44.0)	0.186
Multiple segmental occlusions, n (%)	(45) 24 (53.3)	(20) 8 (40.0)	(25) 16 (64.0)	0.109

* $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; mRS = modified Rankin Scale; IQR = interquartile range; SD = standard deviation; CAD = coronary artery disease; AFib = atrial fibrillation; ICH = intracranial hemorrhage; NIHSS = National Institutes of Health Stroke Scale; SBP = systolic blood pressure; DBP = diastolic blood pressure; LDL = low-density lipoprotein; TICI score = thrombolysis in cerebral infarction score; BAO = basilar artery occlusion.

were conducted by a neurology resident (NF) under the direct supervision of a senior interventional neuroradiologist (JS).

Outcome measures

Primary outcomes were mRS scores at discharge and 90 days, classified as favorable (0–3) or unfavorable (4–6). Secondary outcomes included infarct size and location using CADS.

Statistical analysis

All statistical analyses were conducted using R/RStudio version 4.3.2 and the tidyverse package. Patients were categorized into two groups based on their mRS and CADS scores (favorable outcomes [mRS 0–3] and unfavorable outcomes [mRS 4–6]). Continuous variables (e.g., age, NIHSS, treatment times) were reported as medians with interquartile ranges (IQR), and group comparisons were made using the Mann–Whitney U test. Pearson's chi-square test was applied to compare nominal and ordinal variables between groups. A $p < 0.05$ was considered statistically significant.

Statistical analyses were conducted using ordinal logistic regression to assess the shift in mRS scores across different groups of TICI and CADS categories. Patients were divided into TICI 0–2a versus TICI 2b–3 groups and CADS ≤ 3 versus CADS > 3 groups.

Odds ratios (OR) were calculated to estimate the likelihood of a shift toward more favorable outcomes (mRS 0–3) within each group. A 95% confidence interval (CI) and p -values were used to determine statistical significance. Data visualization included ordinal shift bar plots to display mRS distribution across TICI and CADS groups.

Results

A total of 48 patients were included in the study, divided into two groups based on 90-day mRS scores: mRS ≤ 3 ($n = 21$, 43.8%) and mRS > 3 ($n = 27$, 56.3%). Demographic and baseline characteristics are summarized in Table 1.

Patients in the mRS ≤ 3 group were significantly younger (median age 64.0 years, IQR 48.0–73.0) compared to those in the mRS > 3 group (median age 73.0 years, IQR 66.0–83.0; $p = 0.031$). They also had a lower NIHSS at presentation (median 8, IQR 4–16 vs. 16, IQR 10–21; $p = 0.018$) and a higher frequency of successful reperfusion (mTICI 2b–3 in 81.0% vs. 48.1%; $p = 0.020$).

Thirty patients underwent follow-up DWI-MRI (Table 2). These patients were dichotomized into CADS ≤ 3 ($n = 15$) and CADS > 3 ($n = 15$). Patients with CADS ≤ 3 had significantly lower 90-day mRS scores (median 3, IQR 2–6 vs. 5, IQR 5–6; $p = 0.026$), lower NIHSS at presentation (median 12, IQR 9–17 vs.

Table 2. Patient demographic, clinical characteristics and stroke presentation details by CADS

	Total N = 30	CADS ≤ 3 n = 15	CADS > 3 n = 15	P-value
Age, yr, median (IQR)	66.5 (49.5–76.0)	66.0 (48.0–74.0)	68.0 (60.5–77.0)	0.468
Male, n (%)	21 (70.0)	11 (73.3)	10 (66.7)	0.690
Hyperlipidemia, n (%)	(28) 16 (57.1)	10 (66.7)	(13) 6 (46.2)	0.274
Hypertension, n (%)	(28) 14 (50.0)	7 (46.7)	(13) 7 (53.8)	0.705
Smoking, n (%)	(15) 4 (26.7)	(8) 2 (25.0)	(7) 2 (28.6)	0.876
CAD, n (%)	(28) 6 (21.4)	5 (33.3)	(13) 1 (7.7)	0.099
Diabetes, n (%)	(29) 10 (34.5)	4 (26.7)	(14) 6 (42.9)	0.359
AFib, n (%)	(28) 3 (10.7)	3 (20.0)	(13) 0 (0)	0.088
Prior stroke, n (%)	(28) 5 (17.9)	3 (20.0)	(13) 2 (15.4)	0.751
Prior ICH, n (%)	(28) 1 (3.6)	0 (0)	(13) 1 (7.7)	0.274
Wake-up stroke, n (%)	(29) 7 (24.1)	4 (26.7)	(14) 3 (21.4)	0.742
90-day mRS, median, (IQR)	5 (2–6)	3 (2–6)	5 (5–6)	0.026*
NIHSS at presentation, median (IQR)	(29) 14 (10–20)	12 (9–17)	(14) 19 (13–23)	0.047*
SBP, mmHg, mean (SD)	(25) 166.9 (33.6)	(13) 172.1 (34.4)	(12) 161.3 (33.3)	0.437
DBP, mmHg, mean (SD)	(25) 87.4 (12.5)	(13) 86.3 (13.5)	(12) 88.5 (11.9)	0.672
Blood glucose, mmol/L (SD)	8.9 (3.6)	8.4 (3.3)	9.4 (3.9)	0.450
Hemoglobin A1c, mmol/mol (SD)	(17) 6.5 (1.8)	(7) 5.9 (1.0)	(10) 7.0 (2.1)	0.247
LDL, mmol/L, SD	(14) 2.5 (0.8)	(7) 2.5 (0.8)	(7) 2.5 (0.9)	0.959
Onset to arrival to HSC, minutes, median, (IQR)	170.5 (106.0–387.5)	152.0 (117.5–367.0)	171.0 (92.5–376.0)	0.967
Intravenous thrombolysis, n (%)	10 (33.3)	4 (26.7)	6 (40.0)	0.439
TICI 2b–3, n (%)	15 (50)	7 (46.7)	8 (53.3)	0.713
Tip of BAO, n (%)	(28) 18 (64.3)	(13) 8 (61.5)	10 (66.7)	0.778
Middle of BAO, n (%)	(28) 17 (60.7)	(13) 6 (46.2)	11 (73.3)	0.142
Distal of BAO, n (%)	(28) 13 (46.4)	(13) 4 (30.8)	9 (60.0)	0.122
V4-BAO, n (%)	(28) 12 (42.9)	(13) 5 (38.5)	7 (46.7)	0.662
Multiple segmental occlusions, n (%)	(28) 19 (67.9)	(13) 6 (46.2)	13 (86.7)	0.022*

*P < 0.05; ** P < 0.01; *** P < 0.001; CADS = Critical Area Diffusion Score; IQR = interquartile range; SD = standard deviation; CAD = coronary artery disease; AFib = atrial fibrillation; ICH = intracranial hemorrhage; mRS = modified Rankin Scale; NIHSS = National Institute of Health Stroke Scale; SBP = systolic blood pressure; DBP = diastolic blood pressure; LDL = low-density lipoprotein; HSC = Health Sciences Centre (Winnipeg, Manitoba); TICI score = thrombolysis in cerebral infarction score; BAO = basilar artery occlusion.

Table 3. Comparison of clinical outcomes of patients by CADS > 3 and CADS ≤ 3

	Total N = 30	CADS ≤ 3 n = 15	CADS > 3 n = 15	P-value
TICI 2b–3, n (%)	15 (50.0)	7 (46.7)	8 (53.3)	0.713
Discharge mRS, median, (IQR)	5 (3–6)	4 (3–6)	5 (5–6)	0.047*
Discharge mRS, 0–2 (%)	4 (13.3)	4 (26.7)	0	0.032*
Discharge mRS, 0–3 (%)	8 (26.7)	7 (46.7)	1 (6.7)	0.013*
Hospital mortality, n (%)	10 (33.3)	4 (26.7)	6 (40.0)	0.599
90-day mRS, median, (IQR)	5 (2–6)	3 (2–6)	5 (5–6)	0.026*
90-day mRS, 0–2, n (%)	8 (26.7)	7 (46.7)	1 (6.7)	0.013*
90-day mRS, 0–3, n (%)	10 (33.3)	8 (53.3)	2 (13.3)	0.020*
90-day mortality, n (%)	11 (36.7)	4 (26.7)	7 (46.7)	0.389

*P < 0.05; ** P < 0.01; *** P < 0.001; CADS = Critical Area Diffusion Score; TICI score = thrombolysis in cerebral infarction score; mRS = modified Rankin Scale.




Figure 2. Distribution of modified Rankin Scale scores by Critical Area Diffusion Score (CADS) > 3 and CADS ≤ 3.




Figure 3. Distribution of modified Rankin Scale scores by thrombolysis in cerebral infarction (TICI) 0-2a and TICI 2b-3.

Table 4. Univariate and multivariate analysis of CADS and predictors of favorable outcomes in BAO patients

	Univariate			Multivariate		
	OR	95% CI	P-value	OR	95% CI	P-value
CADS ≤ 3	10.89	1.57–222.09	0.038*	7.94	0.65–245.34	0.144
Reperfusion	2.89	0.74–14.53	0.149	12.45	0.77–670.48	0.124
Age scaled by 10 years	0.76	0.52–1.09	0.144	0.78	0.26–2.19	0.643
Gender	1.02	0.26–3.68	0.978	0.65	0.01–45.09	0.834
Baseline NIHSS	0.86	0.76–0.95	0.007**	0.82	0.063–0.98	0.070

*P < 0.05; ** P < 0.01; *** P < 0.001; OR = odds ratio; CI = confidence interval; CADS = Critical Area Diffusion Score; NIHSS = National Institute of Health Stroke Scale.

Table 5. Predictive power of CADS and reperfusion adjusted for baseline NIHSS and age

	Univariate			Multivariate		
	OR	95% CI	P-value	OR	95% CI	P-value
CADS ≤ 3	10.89	1.57–222.09	0.038*	7.83	0.65–237.58	0.144
Reperfusion	2.89	0.74–14.53	0.149	13.72	0.88–602.48	0.102
Age scaled by 10 years	0.76	0.52–1.09	0.144	0.85	0.39–1.83	0.658
Baseline NIHSS	0.86	0.76–0.95	0.007**	0.82	0.64–0.97	0.049*

* $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; OR = odds ratio; CI = confidence interval; CADS = Critical Area Diffusion Score; NIHSS = National Institute of Health Stroke Scale.

Table 6. Impact of CADS, reperfusion and NIHSS on predicting favorable outcomes in BAO patients

	Univariate			Multivariate		
	OR	95% CI	P-value	OR	95% CI	P-value
CADS ≤ 3	10.89	1.57–222.09	0.038*	9.05	0.78–264.13	0.113
Reperfusion	2.89	0.74–14.53	0.149	18.8	1.63–659.96	0.044*
Baseline NIHSS	0.86	0.76–0.95	0.007**	0.82	0.65–0.98	0.048*

* $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; OR = odds ratio; CI = confidence interval; CADS = Critical Area Diffusion Score; NIHSS = National Institute of Health Stroke Scale.

19, IQR 13–23; $p = 0.047$) and fewer multiple segmental occlusions (46.2% vs. 86.7%).

Table 3 compares clinical outcomes between patients with CADS > 3 and CADS ≤ 3 . The results show significantly lower mRS scores at discharge ($p = 0.013$) and 90 days ($p = 0.020$) for CADS ≤ 3 patients.

Figures 2 and 3 show an mRS ordinal shift analysis for CADS and TICI scores, respectively. Patients with CADS ≤ 3 had a significantly higher odds for favorable outcomes (mRS 0–3) compared to those with CADS > 3 (cOR = 5.2, 95% CI = 1.3–22.3, $p = 0.022$). Patients with TICI 2b–3 had significantly higher odds for favorable outcomes (mRS 0–3) compared to those with TICI 0–2a (cOR = 3.4, 95% CI = 1.1–11.3, $p = 0.036$).

The ROC curve analysis shows the predictive accuracy of CADS and TICI in determining favorable outcomes (mRS 0–3). The area under the curve (AUC) for CADS is 0.70, indicating a good ability to predict favorable outcomes. In contrast, the AUC for TICI is 0.66, which demonstrates similar predictive power.

When examined under a univariate logistic regression, CADS ≤ 3 is a strong predictor of favorable outcomes (OR = 10.89, 95% CI = 1.57–222.09, $p = 0.038$), and per-unit increases in baseline NIHSS highly predict slightly worse outcomes (OR = 0.86, 95% CI = 0.76–0.95, $p = 0.007$) (Table 4). In a multivariate logistic regression, successful reperfusion indicates considerably increased odds of favorable outcomes when controlling for CADS ≤ 3 and baseline NIHSS (OR = 18.8, 95% CI = 1.63–659.96, $p = 0.044$). Similarly, one-unit increases in baseline NIHSS decrease the odds of favorable outcomes by 18% (OR = 0.82, 95% CI = 0.65–0.98, $p = 0.048$) when controlling for CADS ≤ 3 and successful reperfusion. On multivariate analysis, CADS ≤ 3 was not found to be a significant predictor of favorable outcomes (OR = 9.05, 95% CI = 0.78–264.13, $p = 0.113$) (Tables 5 and 6).

Discussion

Our study identified several key factors influencing the outcomes of BAO stroke patients undergoing EVT, including age, NIHSS score at presentation, successful reperfusion as evidenced by TICI

scores and the extent of infarction post-reperfusion assessed using the CADS. These factors collectively contribute to the diverse recovery trajectories observed in BAO patients.

Age and NIHSS at presentation

Patients who achieved a favorable outcome (mRS ≤ 3) at 90 days were significantly younger and presented with lower NIHSS scores compared to those with less favorable outcomes (mRS > 3). Specifically, the median age for the favorable outcome group was 64.0 years versus 73.0 years for the less favorable group ($p = 0.031$), and the median NIHSS scores were 8 versus 16, respectively ($p = 0.018$). These findings align with existing literature that identifies younger age and lower baseline NIHSS scores as critical predictors of better recovery in stroke patients.^{11,16} Younger patients may have better neuroplasticity and fewer comorbidities, contributing to improved outcomes.¹⁹

Impact of successful reperfusion

Our results emphasize the significant role of successful reperfusion in functional recovery. Patients achieving TICI 2b–3 scores demonstrated higher rates of favorable outcomes compared to those with lower TICI scores (81.0% vs. 48.1%; $p = 0.020$). This underscores the importance of timely and effective reperfusion therapies in BAO stroke management. Previous trials, such as ATTENTION and BAOCHÉ, have demonstrated the benefits of achieving successful reperfusion in reducing disability and mortality among BAO patients.^{5,7,8} However, our findings also suggest that successful reperfusion alone may not guarantee favorable outcomes, as other factors like baseline stroke severity and patient age play significant roles.

Role of CADS

While age, NIHSS scores and TICI scores are established predictors of outcomes in BAO stroke,^{11,16} the role of imaging markers such as CAPS has been less explored. Cereda et al.¹⁷ introduced CAPS using CT and MR perfusion imaging before EVT to assess the severity of hypoperfusion and predict outcomes. In contrast, our

CADS assesses infarct size and location based explicitly on DWI-MRI after EVT, focusing on confirmed infarct regions within predefined critical areas of the posterior circulation (cerebellum, pons, midbrain and/or thalamus). Figure 1 illustrates the scoring of CADS based on infarct distribution.

Another study from the same group demonstrated that pre-procedural cerebral perfusion imaging can effectively predict the final infarct volume in patients undergoing basilar artery thrombectomy.²⁰ This study found that specific perfusion parameters correlated with the extent of irreversible brain damage after EVT, highlighting the importance of imaging in outcome prediction and individualized treatment planning.

Karamchandani et al.¹⁸ demonstrated a correlation between pre-EVT perfusion parameters (original CAPS) and post-EVT infarct volume on DWI, validating pre-EVT imaging's predictive role. Our study extends this by highlighting the clinical relevance of post-EVT imaging: identifying precise infarct locations within critical brainstem areas allows precise prognostic stratification for patients who have undergone successful reperfusion. While pre-EVT imaging is critical for guiding treatment decisions, post-EVT CADS adds significant value by providing an accurate prognosis for individual patients. The CADS score offers a structured, region-based approach to quantifying brainstem infarction, which can aid in prognostication, family counseling and rehabilitation planning.

Patients with CADS ≤ 3 exhibited significantly better median mRS scores at 90 days compared to those with CADS > 3 (median mRS 3 vs. 5; $p = 0.020$). This suggests that lower CADS scores correlate with better functional outcomes, supporting the potential utility of CADS in assessing recovery potential.

However, in our multivariate analysis, CADS did not remain an independent predictor of favorable outcomes when adjusted for successful reperfusion and baseline NIHSS scores (OR = 9.05; 95% CI = 0.78–264.13; $p = 0.113$). This may be due to the limited sample size and the possibility that CADS is interrelated with other clinical variables. This highlights the complexities in predicting stroke outcomes and suggests that while CADS is a useful tool, it should be considered alongside other significant factors like reperfusion success.

Our study aligns with the multifaceted approach to prognostication in BAO stroke suggested by recent research. For instance, the Charlotte Large Artery Occlusion Endovascular Therapy Outcome Score incorporates factors such as age, NIHSS score, glucose level and pre-thrombectomy imaging findings to predict outcomes.¹⁸ This supports the notion that a combination of clinical and imaging markers, rather than a single factor, is crucial for accurate outcome prediction in BAO stroke.

Given these insights, our study not only reaffirms the multifactorial nature of stroke outcomes influenced by traditional clinical assessments but also introduces post-EVT DWI as a valuable tool in this predictive landscape. By integrating CADS with other established markers, we could potentially develop a more precise predictive model for long-term recovery.

Limitations

This study is constrained by its retrospective nature and the relatively small cohort size. A notable limitation is the application of the CADS post-EVT, differing from its original use pre-EVT, which may affect comparability. While demonstrating the utility of post-EVT DWI in predicting outcomes, future research should

explore if a combined pre- and post-EVT imaging approach could further refine prediction accuracy.

Additionally, prospective trials are needed to validate CADS as a reliable predictor of long-term outcomes in BAO patients. Future research should investigate whether CADS, when combined with other markers such as NIHSS and collateral flow, could offer an even more accurate predictive model for long-term recovery.

Conclusion

Our study identifies age, NIHSS scores and successful reperfusion as significant predictors of recovery outcomes in patients with BAO. While lower post-EVT CADS scores were associated with better outcomes in univariate analysis, CADS did not remain an independent predictor when controlling for other factors. These findings suggest that while advanced imaging markers like CADS have potential utility, they should be interpreted alongside established clinical indicators.

Author contributions. NF collected the data, interpreted the imaging findings and drafted the manuscript. MA assisted with statistical analysis and data interpretation. SA contributed to data collection and ethics approval submission. JS provided conceptual guidance, oversaw all stages of the project development and offered critical revisions to the final manuscript.

Funding statement. No funding was received for the preparation of this review article.

Competing interests. The authors declare no competing interests.

References

1. Rennert RC, Wali AR, Steinberg JA, et al. Epidemiology, natural history, and clinical presentation of large vessel ischemic stroke, *Neurosurgery*. 2019;85(suppl 1):S4–S8. DOI: [10.1093/neuros/nyz042](https://doi.org/10.1093/neuros/nyz042).
2. Langezaal LCM, van der Hoeven EJ, Mont'Alverne FJA, et al. Endovascular therapy for stroke due to basilar-artery occlusion. *New Engl J Med*. 2021;384:1910–20. DOI: [10.1056/nejmoa2030297](https://doi.org/10.1056/nejmoa2030297).
3. Solla DJF, Argolo FC, Budohoski KP, Kolias AG, Caldas JGMP, Oliveira-Filho J. Is more evidence needed for thrombectomy in basilar artery occlusion? The BASICS and BEST meta-analytical approaches. *Stroke Vasc Neurol*. 2021;6:671–2. DOI: [10.1136/svn-2020-000701](https://doi.org/10.1136/svn-2020-000701).
4. Nguyen TN, Strbian D. Endovascular therapy for stroke due to basilar artery occlusion: a BASIC challenge at BEST. *Stroke*. 2021;52:3410–3413. DOI: [10.1161/STROKEAHA.121.035948](https://doi.org/10.1161/STROKEAHA.121.035948).
5. Tao C, Nogueira RG, Zhu Y, et al. Trial of endovascular treatment of acute basilar-artery occlusion. *New Engl J Med*. 2022;387:1361–72. DOI: [10.1056/nejmoa2206317](https://doi.org/10.1056/nejmoa2206317).
6. Liu X, Dai Q, Ye R, et al. Endovascular treatment versus standard medical treatment for vertebrobasilar artery occlusion (BEST): an open-label, randomised controlled trial. *Lancet Neurol*. 2020;19:115–22. DOI: [10.1016/S1474-4422\(19\)30395-3](https://doi.org/10.1016/S1474-4422(19)30395-3).
7. Alemseged F, Nguyen TN, Coutts SB, et al. Endovascular thrombectomy for basilar artery occlusion: translating research findings into clinical practice. *Lancet Neurol*. 2023;22:330–7. DOI: [10.1016/S1474-4422\(22\)00483-5](https://doi.org/10.1016/S1474-4422(22)00483-5).
8. Jovin TG, Li C, Wu L, et al. Trial of thrombectomy 6 to 24 Hours after stroke due to basilar-artery occlusion. *New Engl J Med*. 2022;387:1373–84. DOI: [10.1056/nejmoa2207576](https://doi.org/10.1056/nejmoa2207576).
9. Sun X, Tong X, Gao F, Lao H, Miao Z. Endovascular treatment for acute basilar artery occlusion: a single center retrospective observational study. *BMC Neurol*. 2019;19(1):315. DOI: [10.1186/s12883-019-1551-8](https://doi.org/10.1186/s12883-019-1551-8).
10. Pirson F.A. V, Boedt N, Brouwer J, et al. Endovascular treatment for posterior circulation stroke in routine clinical practice: results of the multicenter randomized clinical trial of endovascular treatment for acute ischemic stroke in the Netherlands registry. *Stroke*. 2022;29:758–768. DOI: [10.1161/STROKEAHA.121.034786](https://doi.org/10.1161/STROKEAHA.121.034786).

11. Bouslama M, Haussen DC, Aghaebrahim A, et al. Predictors of good outcome after endovascular therapy for vertebrobasilar occlusion stroke. *Stroke*. 2017;48:3252–3257. DOI: [10.1161/STROKEAHA.117.018270](https://doi.org/10.1161/STROKEAHA.117.018270).
12. Guillaume M, Lapergue B, Gory B, et al. Rapid successful reperfusion of basilar artery occlusion strokes with pretreatment diffusion-weighted imaging posterior-circulation ASPECTS <8 is associated with good outcome. *J Am Heart Assoc*. 2019;8(10):e010962. DOI: [10.1161/JAHA.118.010962](https://doi.org/10.1161/JAHA.118.010962).
13. Strbian D, Sairanen T, Silvennoinen H, Salonen O, Kaste M, Lindsberg PJ. Thrombolysis of basilar artery occlusion: impact of baseline ischemia and time. *Ann Neurol*. 2013;73:688–694. DOI: [10.1002/ana.23904](https://doi.org/10.1002/ana.23904).
14. Gory B, Mazighi M, Labreuche J, et al. Predictors for mortality after mechanical thrombectomy of acute basilar artery occlusion. *Cerebrovasc Dis*. 2018;45:61–7. DOI: [10.1159/000486690](https://doi.org/10.1159/000486690).
15. Mahmoudi M, Dargazanli C, Cagnazzo F, et al. Predictors of favorable outcome after endovascular thrombectomy in MRI: selected patients with acute basilar artery occlusion. *Am J Neuroradiol*. 2020;41:1670–6. DOI: [10.3174/ajnr.A6741](https://doi.org/10.3174/ajnr.A6741).
16. Dornák T, Herzig R, Školoudík D, et al. Outcome predictors in acute basilar artery occlusion. *Can J Neurol Sci*. 2014;41:368–374. DOI: [10.1017/S0317167100017327](https://doi.org/10.1017/S0317167100017327).
17. Cereda CW, Bianco G, Mlynash M, et al. Perfusion imaging predicts favorable outcomes after basilar artery thrombectomy. *Ann Neurol*. 2022;91:23–32. DOI: [10.1002/ana.26272](https://doi.org/10.1002/ana.26272).
18. Karamchandani RR, Satyanarayana S, Yang H, et al. The Charlotte large artery occlusion endovascular therapy outcome score compares favorably to the critical area perfusion score for prognostication before basilar thrombectomy. *J Stroke Cerebrovasc Dis*. 2023;32:107147. DOI: [10.1016/j.jstrokecerebrovasdis.2023.107147](https://doi.org/10.1016/j.jstrokecerebrovasdis.2023.107147).
19. Liew SL, Schweighofer N, Cole JH, et al. Association of brain age, lesion volume, and functional outcome in patients with stroke. *Neurology*. 2023;100:e2103–e2113. DOI: [10.1212/WNL.0000000000207219](https://doi.org/10.1212/WNL.0000000000207219).
20. Yuen N, Mlynash M, O’Riordan A, et al. Cerebral perfusion imaging predicts final infarct volume after basilar artery thrombectomy. *J Stroke Cerebrovasc Dis*. 2023;32:106866. DOI: [10.1016/j.jstrokecerebrovasdis.2022.106866](https://doi.org/10.1016/j.jstrokecerebrovasdis.2022.106866).